Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma

Philadelphia – Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets will present multispecific molecules targeting GPRC5D, BCMA, and […]

Webinar presented by Integral Molecular and Fierce Biotech – Conquering Undruggable Targets to Obtain Preclinical Antibodies

Thursday, September 14, 2023 8 am PT, 11 am ET, 17:00 CET Watch the webinar Despite the remarkable growth of antibody-based therapies in recent […]